We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Intra-Cellular

News List

Intra-Cellular nabs nod for schizophrenia drug after FDA twists fiercepharma
December 31, 2019
Intra-Cellular Therapies had quite a journey toward an FDA decision on its antipsychotic contender. It involved mixed clinical data, a canceled advisory committee meeting and a three-month review extension.
Intra-Cellular Therapies Provides Lumateperone Regulatory Update drugs
September 16, 2019
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders ...
Intra-Cellular Therapies Announces Positive Phase III Results contractpharma
July 17, 2019
Lumateperone achieves topline results in the treatment of major depressive episodes associated with Bipolar I or Bipolar II disorder.